Efm192a

Human breast cancer cell lines (SK‐BR‐3, AU565, BT474, MDA‐MB‐361, EFM192A, HCC1954, JIMT1, and ZR‐75‐30) were obtained from the American Type Culture Collection (ATCC) and were all cultured in high‐glucose DMEM (Gibco) supplemented with 10% foetal bovine serum (Gibco), and 100 μg/ml penicillin/streptomycin (Invitrogen). MCF‐10A and MCF‐10CA1a cells were obtained from the Shanghai Cell Bank Type Culture Collection Committee and cultured in DMEM/F12 (Gibco) with 10% horse serum (Gibco), 10 μg/ml insulin (Sigma), 100 μg/ml penicillin/streptomycin (Invitrogen), 0.5 μg/ml hydrocortisone (Sigma), 20 ng/ml EGF (Invitrogen) and 1 ng/ml cholera toxin (Sigma). All cell lines were mycoplasma negative and passed short‐tandem repeat (STR) test verification (Supplementary Data).

The human breast carcinoma cell lines (BT-549, MDA-MB-231, BT-474, EFM-192A, MDA-MB-453, SK-BR-3, and ZR-75-1) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in RPMI, except for MDA-MB-453 and SK-BR-3 in DMEM. The media were added with 10% of FBS, 1% of penicillin, 1% of streptomycin, and 1% of L-glutamine. Approximately 20% of FBS was used for EFM-192A and BT-474 cells. Medium for BT-474 was supplemented with 10 μg/mL of insulin. All reagents, unless specified, are from SigmaAldrich (St. Louis, MO, USA). HGF (recombinant human hepatocyte growth factor NS0-expressed) was purchased from R&D systems (Minneapolis, MN, USA). MET tyrosine kinase inhibitor JNJ-38877605 (JNJ) was purchased from Selleckchem (Houston, TX, USA).